As part of the Resolution Membership Program, collectors will receive 15% off all submissions, expedited turnaround times, ...

Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...

Watt’s online MSc Computer Science blends academic expertise with practical, real-world teaching, including algorithm demos ...

Overview: The demand for programming skills in 2026 centres around versatility, performance, and scalability as companies ramp up AI, cloud, and web services.La ...

Overview: Avoiding common Java mistakes significantly improves application speed, memory use, and overall stability.Choosing the right data structures and closi ...

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today ...

Wallbridge Mining Company Limited (TSX: WM, OTCQX: WLBMF) ('Wallbridge” or the 'Company”) is pleased to announce its 2026 ...

Investing.com -- Structure Therapeutics Inc ADR (NASDAQ:GPCR) stock soared 28.8% in premarket trading Monday after the company announced positive topline data from its ACCESS clinical program for ...

Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...

The fund seeks to enable researchers to make leaps rather than incremental advances in the natural sciences and engineering.

Structure Therapeutics (GPCR) announced positive topline data from the ACCESS clinical program of aleniglipron for the treatment of people living ...

San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...